Search

Displaying results 5061 - 5070 of 7018 in total
  1. Drug

    Balipodect

    go.drugbank.com/drugs/DB14774
    Investigational

    Balipodect is under investigation in clinical trial NCT01892189 (Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults).

  2. Drug

    Actinium Ac 225 dotatate

    go.drugbank.com/drugs/DB23632
    Investigational

    Actinium Ac 225 dotatate is a biologic drug. … Actinium Ac 225 dotatate is under investigation in clinical trial NCT07150806 (RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma).

    Synonyms: Actinium Ac 225 dotatate, Actinium Ac-225 dotatate
  3. Drug

    S-23

    go.drugbank.com/drugs/DB07419
    Experimental

    An androgen receptor modulator.

  4. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341

  5. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington … ACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases.

  6. Drug

    GS-100

    go.drugbank.com/drugs/DB18337
    Investigational

    GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence

  7. Drug

    ABT-639

    go.drugbank.com/drugs/DB15055
    Investigational

    ABT-639 is under investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain).

  8. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled[L31728]. … PF-07304814 is a small molecule prodrug that targets the 3CL<sup>pro</sup> protease (M<sup>pro)</sup>, which is used by viruses like SARS-CoV-2 to assemble and multiply[L31718].

  9. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

  10. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).